AID  Vol.3 No.4 , December 2013
Septic Shock after Intravesical BCG Instillation—A Case Report
Abstract: Bacillus Calmette-Guérin (BCG) is a live attenuated form of Mycobacterium bovis, initially used in medicine as a vaccination agent only. The discovery of its antineoplastic effects in bladder cancer has led to the widespread recognition of BCG intravesical instillation as a therapeutic option. Although sepsis following BCG intravesical instillation is rare, it is nonetheless a dreadful and potentially fatal complication. Therapy usually relies on antituberculous therapy and steroids, alongside with intensive care unit admission. The authors report a case of a 67-year-old male patient who developed septic shock with multiple organ dysfunction after intravesical BCG instillation and review the currently available knowledge concerning the risk factors, diagnosis, management and prevention of BCG sepsis.  
Cite this paper: C. Figueiredo, D. Póvoas, C. Alves, A. Ferreira, P. Figueiredo, T. Carvalho, A. Ramos, L. Santos and A. Sarmento, "Septic Shock after Intravesical BCG Instillation—A Case Report," Advances in Infectious Diseases, Vol. 3 No. 4, 2013, pp. 243-247. doi: 10.4236/aid.2013.34036.

[1]   U. V. A. Silva, L. S. Viana, P. T. O. Castro, R. Almeida and R. S. P. daSilva, “Fatal Sepsis after Intravesical Instillation of BCG—Case Report,” Rev Bras Ter Intensiva, Vol. 23, No. 1, 2011, pp. 104-107.

[2]   S. Brandau and H. Suttmann, “Thirty Years of BCG Immunotherapy for Non-Muscle Invasive Bladder Cancer: A Success Story with Room for Improvement,” Biomed Pharmaceuticals, Vol. 61, No. 6, 2007, pp. 299-305.

[3]   M. J. Barza, J. H. Blum and F. M. Graeme-Cook, “A 57-Year-Old Man with Fever and Jaundice after Intravesical Instillation of Bacille Calmette-Guérin for Bladder Cancer,” The New England Journal of Medicine, Vol. 339, No. 12, 1998, p. 831.

[4]   D. L. Lamm, “Efficacy and Safety of Bacille CalmetteGuérin Immunotherapy in Superficial Bladder Cancer,” Clinical Infectious Diseases, Vol. 31, No. S3, 2000, pp. S86-S90.

[5]   C. French, L. Hickey and D. Bell, “Caseating Granulomas on the Glans Penis as a Complication of Bacille CalmetteGuérin Intravesical Therapy,” Reviews in Urology, Vol. 3, No. 1, 2001, pp. 36-39.

[6]   H. M. Frey, “Septic Shock in a 3l-Year-Old Male with a Superficial Bladder Tumor,” Clinical Infectious Diseases, Vol. 2, No. 4, 1998, pp. 226-229.

[7]   O. Gonzalez, D. Musher, I. Brar, S. Furgeson, M. Boktour, E. Septimus, R. Hamill and E. Graviss, “Spectrum of Bacille Calmette-Guérin (BCG) Infection after Intravesical BCG Immunotherapy,” Clinical Infectious Diseases, Vol. 36, No. 2, 2003, pp. 140-148.

[8]   F. Saint, L. Salomon, R. Quintela, A. Cicco, C. C. Abbou and D. K. Chopin, “Classification, Facteurs Favorisants, Prévention et Traitement des Effets Indésirables Associés au Bacille de Calmette-Guérin dans le Traitement des Tumeurs Superficielles de Vessie,” Annales of Urology, Vol. 36, No. 2, 2002, pp. 120-131.

[9]   E. Talbot, C. F. von Reyn and E. L. Baron, “Mycobacterium Bovis,” 2013.

[10]   C. Durek, A. Jurczok, H. Werner, D. Jocham and A. Bohle, “Optimal Treatment of Systemic Bacillus CalmetteGuerin Infection: Investigations in an Animal Model,” Journal of Urology, Vol. 168, No. 2, 2002, pp. 826-831.

[11]   C. Durek, S. Rüsch-Gerdes, D. Jocham and A. Böhle, “Sensitivity of BCG to Modern Antibiotics,” European Urology, Vol. 37, No. S1, 2000, p. s21.

[12]   S. C. Koukol, J. I. DeHaven, D. R. Riggs and D. L. Lamm, “Drug Therapy of Bacillus Calmette-Guérin Sepsis,” Urological Research, Vol. 22, No. 6, 1995, pp. 373-376.

[13]   M. Elkabani, J. N. Greene, A. L. Vincent, S. Van Hook and R. L. Sandin, “Disseminated Mycobacterium bovis after Intravesicular Bacillus Calmette-Guérin Treatments for Bladder Cancer,” Cancer Contact, Vol. 7, No. 5, 2000, pp. 476-481.

[14]   R. Wittes, L. Klotz and U. Kosecka, “Severe Bacillus Calmette-Guérin Cystitis Responds to Systemic Steroids When Antituberculous Drugs and Local Steroids Fail,” Journal of Urology, Vol. 161, No. 5, 1999, p. 1568.

[15]   A. Steg, C. Leleu, B. Debré, et al., “Systemic Bacillus Calmette-Guérin Infection in Patients Treated by Intravesical BCG Therapy for Superficial Bladder Cancer,” Progress in Clinical and Biological Research, Vol. 310, No. 1, 1989, p. 325.

[16]   J. I. DeHaven, C. Traynellis, D. R. Riggs, E. Ting and D. L. Lamm, “Antibiotic and Steroid Therapy of Massive Systemic Bacillus Calmette-Guérin Toxicity,” Journal of Urology, Vol. 147, No. 3, 1992, pp. 738-742.

[17]   D. L. Lamm, “Complications of Bacillus Calmette-Guérin Immunotherapy,” Urologic Clinics of North America, Vol. 19, No. 3, 1992, pp. 565-572.

[18]   Y. Durán, F. Santos, D. Serentill, P. Montaperto, P. Valencia and C. Solé, “Tuberculosis Miliar in a Patient Treated with Intravesical Instillations of Bacillus CalmetteGuérin,” Med Intensiva, Vol. 30, No. 3, 2006, pp. 116-119.

[19]   A. P. van der Meijden, M. Brausi, V. Zambon, W. Kirkels, C. de Balincourt and R. Sylvester, “Intravesical Instillation of Epirubicin, Bacillus Calmette-Guérin and Bacillus Calmette-Guérin plus Isoniazid for Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Bladder: A European Organization for Research and Treatment of Cancer Genito-Urinary Group Randomized Phase III Trial,” Journal of Urology, Vol. 166, No. 2, 2001, p. 476.

[20]   R. Damiano, M. De Sio, G. Quarto, et al., “Short-Term Administration of Prulifloxacin in Patients with Nonmuscle-Invasive Bladder Cancer: An Effective Option for the Prevention of Bacillus Calmette-Guérin-Induced Toxicity?” BJU International, 2009, Vol. 104, p. 633.